USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
84818
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
0712489
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Ablitech, Inc.
518 N. Main Street Hattiesburg, MS 39401 0000
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2007
Title: SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents
Agency: NSF
Contract: 0712489
Award Amount: $100,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I research research project aims to develop a polymer system for drug eluting coronary stents (DES). The material is expected to provide higher drug loading with a controlled drug release profile, as well as tunable mechanical properties over the lifetime of the stent. This will be accomplished using block terpolymers of specific composition to which drug molecules will be covalently attached. Recent advances in DES technology have increased the success rate of CHD treatment; however, restenosis (re-blockage of the artery through the stent) occurs in 10% of the implanted stents. Also currently available drug eluting coatings deliver the bulk of the loaded drug within the first 48 hours of stent placement, with little to no delivery after 30 days. Thus a new type of stent that can overcome the limitations of current stents would be of significant value.

Principal Investigator:

Lisa K. Kemp
PhD
6013472811
lisa.kemp@ablitech.com

Business Contact:

Lisa K. Kemp
PhD
6013472811
lisa.kemp@ablitech.com
Small Business Information at Submission:

Ablitech, Inc.
518 N. Main Street # 286 Hattiesburg, MS 39401

EIN/Tax ID: 204833026
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No